A New Treatment
The federal government has announced that Vabysmo™ (Faricimab) had been funded on the Pharamaceutical Benefits scheme from January 1st 2023 for the treatment of Wet macular degeneration and Diabetic Macular Oedema. Faricimab is a new treatment that has the potential to reduce the frequency of intravitreal injections for patients with both of these diseases. Drug … Read more